vs
BXP, Inc.（BXP）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
BXP, Inc.的季度营收约是Revvity的1.1倍（$872.1M vs $772.1M），BXP, Inc.净利率更高（15.3% vs 12.7%，领先2.5%），Revvity同比增速更快（5.9% vs 0.8%），过去两年Revvity的营收复合增速更高（9.0% vs 1.3%）
BXP是美国头部商业地产投资信托企业，核心业务为持有、运营及开发A级高端写字楼资产，项目覆盖纽约、波士顿、旧金山等美国核心都市圈，服务企业、科技、专业服务等领域的多元租户。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
BXP vs RVTY — 直观对比
营收规模更大
BXP
是对方的1.1倍
$772.1M
营收增速更快
RVTY
高出5.1%
0.8%
净利率更高
BXP
高出2.5%
12.7%
两年增速更快
RVTY
近两年复合增速
1.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $872.1M | $772.1M |
| 净利润 | $133.0M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | — | 14.5% |
| 净利率 | 15.3% | 12.7% |
| 营收同比 | 0.8% | 5.9% |
| 净利润同比 | 53.0% | 3.9% |
| 每股收益（稀释后） | $1.69 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BXPRVTY
| Q1 26 | $872.1M | — | ||
| Q4 25 | $877.1M | $772.1M | ||
| Q3 25 | $871.5M | $698.9M | ||
| Q2 25 | $868.5M | $720.3M | ||
| Q1 25 | $865.2M | $664.8M | ||
| Q4 24 | $858.6M | $729.4M | ||
| Q3 24 | $859.2M | $684.0M | ||
| Q2 24 | $850.5M | $691.7M |
净利润BXPRVTY
| Q1 26 | $133.0M | — | ||
| Q4 25 | $248.4M | $98.4M | ||
| Q3 25 | $-121.7M | $46.7M | ||
| Q2 25 | $89.0M | $53.9M | ||
| Q1 25 | $61.2M | $42.2M | ||
| Q4 24 | $-228.9M | $94.6M | ||
| Q3 24 | $83.6M | $94.4M | ||
| Q2 24 | $79.6M | $55.4M |
毛利率BXPRVTY
| Q1 26 | — | — | ||
| Q4 25 | 58.8% | — | ||
| Q3 25 | 59.3% | 53.6% | ||
| Q2 25 | 59.2% | 54.5% | ||
| Q1 25 | 59.2% | 56.5% | ||
| Q4 24 | 59.7% | — | ||
| Q3 24 | 59.5% | 56.3% | ||
| Q2 24 | 59.8% | 55.7% |
营业利润率BXPRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | 14.5% | ||
| Q3 25 | — | 11.7% | ||
| Q2 25 | — | 12.6% | ||
| Q1 25 | — | 10.9% | ||
| Q4 24 | — | 16.3% | ||
| Q3 24 | — | 14.3% | ||
| Q2 24 | — | 12.4% |
净利率BXPRVTY
| Q1 26 | 15.3% | — | ||
| Q4 25 | 28.3% | 12.7% | ||
| Q3 25 | -14.0% | 6.7% | ||
| Q2 25 | 10.2% | 7.5% | ||
| Q1 25 | 7.1% | 6.4% | ||
| Q4 24 | -26.7% | 13.0% | ||
| Q3 24 | 9.7% | 13.8% | ||
| Q2 24 | 9.4% | 8.0% |
每股收益（稀释后）BXPRVTY
| Q1 26 | $1.69 | — | ||
| Q4 25 | $1.56 | $0.86 | ||
| Q3 25 | $-0.77 | $0.40 | ||
| Q2 25 | $0.56 | $0.46 | ||
| Q1 25 | $0.39 | $0.35 | ||
| Q4 24 | $-1.46 | $0.77 | ||
| Q3 24 | $0.53 | $0.77 | ||
| Q2 24 | $0.51 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $512.8M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $7.7B | $7.3B |
| 总资产 | $25.1B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BXPRVTY
| Q1 26 | $512.8M | — | ||
| Q4 25 | $1.5B | $919.9M | ||
| Q3 25 | $861.1M | $931.4M | ||
| Q2 25 | $447.0M | $991.8M | ||
| Q1 25 | $398.1M | $1.1B | ||
| Q4 24 | $1.3B | $1.2B | ||
| Q3 24 | $1.4B | $1.2B | ||
| Q2 24 | $685.4M | $2.0B |
股东权益BXPRVTY
| Q1 26 | $7.7B | — | ||
| Q4 25 | $5.1B | $7.3B | ||
| Q3 25 | $5.0B | $7.4B | ||
| Q2 25 | $5.3B | $7.6B | ||
| Q1 25 | $5.3B | $7.6B | ||
| Q4 24 | $5.4B | $7.7B | ||
| Q3 24 | $5.8B | $7.9B | ||
| Q2 24 | $5.8B | $7.9B |
总资产BXPRVTY
| Q1 26 | $25.1B | — | ||
| Q4 25 | $26.2B | $12.2B | ||
| Q3 25 | $26.0B | $12.1B | ||
| Q2 25 | $25.6B | $12.4B | ||
| Q1 25 | $25.4B | $12.4B | ||
| Q4 24 | $26.1B | $12.4B | ||
| Q3 24 | $26.4B | $12.8B | ||
| Q2 24 | $25.5B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | 1.5% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流BXPRVTY
| Q1 26 | — | — | ||
| Q4 25 | $407.8M | $182.0M | ||
| Q3 25 | $274.2M | $138.5M | ||
| Q2 25 | $353.1M | $134.3M | ||
| Q1 25 | $210.0M | $128.2M | ||
| Q4 24 | $383.7M | $174.2M | ||
| Q3 24 | $286.1M | $147.9M | ||
| Q2 24 | $367.1M | $158.6M |
自由现金流BXPRVTY
| Q1 26 | — | — | ||
| Q4 25 | $362.7M | $161.8M | ||
| Q3 25 | $231.6M | $120.0M | ||
| Q2 25 | $281.5M | $115.5M | ||
| Q1 25 | $152.6M | $112.2M | ||
| Q4 24 | $312.5M | $149.8M | ||
| Q3 24 | $234.5M | $125.6M | ||
| Q2 24 | $332.4M | $136.6M |
自由现金流率BXPRVTY
| Q1 26 | — | — | ||
| Q4 25 | 41.4% | 21.0% | ||
| Q3 25 | 26.6% | 17.2% | ||
| Q2 25 | 32.4% | 16.0% | ||
| Q1 25 | 17.6% | 16.9% | ||
| Q4 24 | 36.4% | 20.5% | ||
| Q3 24 | 27.3% | 18.4% | ||
| Q2 24 | 39.1% | 19.7% |
资本支出强度BXPRVTY
| Q1 26 | 1.5% | — | ||
| Q4 25 | 5.1% | 2.6% | ||
| Q3 25 | 4.9% | 2.6% | ||
| Q2 25 | 8.2% | 2.6% | ||
| Q1 25 | 6.6% | 2.4% | ||
| Q4 24 | 8.3% | 3.4% | ||
| Q3 24 | 6.0% | 3.3% | ||
| Q2 24 | 4.1% | 3.2% |
现金转化率BXPRVTY
| Q1 26 | — | — | ||
| Q4 25 | 1.64× | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | 3.97× | 2.49× | ||
| Q1 25 | 3.43× | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | 3.42× | 1.57× | ||
| Q2 24 | 4.61× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BXP
| Lease | $818.2M | 94% |
| Parking and other | $30.8M | 4% |
| Development and management services | $9.2M | 1% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
